COVID-19 SALIVA TEST

Service Description

COVID-19 Deep Throat Saliva test (oral fluid). SIMKA Government approved test and SIMKA report.  This is a qualitatively test which detects the SARS-CoV2 nucleocapsid protein antigen in human oral fluid specimen following membrane-based immunoassay. The specimen reacts with the SASR-CoV2 nucleocapsid protein antibody-coating particles in the test line region of the test cassette during the testing. Driven by capillary action, the mixture migrates upward on the membrane chromatographically to react with the SARS-CoV2 nucleocapsid protein antibody in the test line region. When the specimen contains SARS-CoV2 antigens, a coloured line will be present in the test line region. In the absence of antigens to SAR-CoV2, there will be no coloured line in the test region to indicate a negative result. A coloured line will appear at the control reagent to serve as a procedure control as an indicator that the test has been performed correctly. The COVID-19 Deep Throat Saliva test was developed in USA in Yale University and boast an accuracy of 96.9%. The study is a small study involving 160 participants only. Samples were collected by the use of the deep throat antigen rapid test kit and compared against the PCR test. The Sensitivity 93.3% and Specificity 99% for the Deep Throat Saliva test (oral fluid). Currently, in Malaysia, Penang is starting to manufacture these test kits and has been approved for use. There is no need for unpleasant swabs in the nostril and throat. This also reduces the risk of transmission from patient to healthcare workers doing the swabs. 

Cancelation Policy

To cancel please contact us 0128077720 or 07-2557720

Contact Details

• No 71, Jalan Serangkai 4, Taman Bukit Dahlia, Pasir Gudang, 81700

  +60 128077720

  amdclinic71@gmail.com